| PanGenex Provides Updated Time Line for Direct Response Television Program with Partner Incredible Discoveries® to Promote Scientifically Formulated, Condition Specific Dietary Supplements
November 27, 2009 at 4:00 pm
|
| CLEARWATER, Fla.--(BUSINESS WIRE)--PanGenex Corporation (Pink Sheets:PGCX) (“PanGenex” or “the Company”) announced today that it anticipates the release of its long form television program, demonstrating the benefits of Calci-CLEAR™, its patent pending dietary supplement that addresses soft tissue calcification, pursuant to its partnership with Incredible Discoveries® in early 2010. Calci-CLEAR™ is a dietary supplement designed to address soft tissue calc
      
 |
| Ongoing Rights Issue in Karo Bio AB (Publ) – Prospectus Supplement is Published
November 27, 2009 at 12:17 pm
|
| STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Not for release, publication or distribution in Australia, Canada, Japan or the United States. This announcement does not constitute an offer to sell or the solicitation of an offer to buy the securities of Karo Bio AB (publ) (the “Securities”) in Australia, Canada, Japan or the United States or in any other jurisdiction. Securities may not be offered or sold in the United States absent registration or an exemption from registration u
 |
| Research and Markets: Anxiety Therapy Area Pipeline Report - Detailed Information on the Pipeline Status of Anxiety Drugs by Company and by Stage and Latest News and Developments
November 27, 2009 at 11:00 am
|
| DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3365ab/anxiety_therapy_ar) has announced the addition of the "Anxiety Therapy Area Pipeline Report" report to their offering. Life Science Analytics, Anxiety Therapy Area Pipeline Report contains detailed information on the anxiety drug pipeline. This report provides insight into the pipeline status of anxiety drugs by company and by stage as well as a summary of the latest news and developments in this are
 |
| Research and Markets: Optimizing Lifecycle Management: Maximizing Commercial Lifespan Through Label Expansion and Combination Products - Report Now Available
November 27, 2009 at 10:32 am
|
| DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8eba7b/optimizing_lifecyc) has announced the addition of the "Optimizing Lifecycle Management: Maximizing Commercial Lifespan Through Label Expansion and Combination Products" report to their offering. The need to derive the maximum commercial mileage from all components of a drug company's portfolio is clearly evident in an era of falling returns on investment and higher capital costs. This report investig
 |
| Research and Markets: Latin American Pharmaceutical Market Outlook to 2014: Policy Environment, Market Analysis, Forecasts and Growth Opportunities
November 27, 2009 at 10:00 am
|
| DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/b82621/latin_american_pha) has announced the addition of the "Latin American Pharmaceutical Market Outlook To 2014: Policy Environment, Market Analysis, Forecasts and Growth Opportunities" report to their offering. The $28.8bn Latin American market delivered 15.3% y-o-y growth in 2008 as per IMS Health data. The market is expected to grow to $51.3bn in 2014 at a CAGR of 10.1%. Inconsistency in regulatory pr
 |
| Research and Markets: Intranasal Drug Delivery - a Comprehensive Report on the US Market Trends & Analysis
November 27, 2009 at 10:00 am
|
| DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/1b2b29/intranasal_drug_de) has announced the addition of the "Intranasal Drug Delivery - US Market Trends & Analysis" report to their offering. The US intranasal drug delivery market is witnessing an expansion of therapeutic applications from the delivery of conventional local therapeutic drugs to the delivery of systemic therapeutic drugs. The future of the technology hinges onto the effective exploita
 |
| Simulations Plus Sets Date for Fiscal Year 2009 Earnings Release and Conference Call
November 27, 2009 at 9:25 am
|
| LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of software for pharmaceutical discovery and development, announced that it expects to file its 10K-SB annual report with the Securities and Exchange Commission on Monday, November 30, for the 2009 fiscal year ended August 31, 2009. Chairman and CEO Walt Woltosz will host a conference call and webinar to discuss the Company’s performance on Monday afternoon, November 30, at 1:15 PM PST / 4:15 PM EST
 | Media Files
ViewMedia?mgid=70096&vid=2 (2 KB)
|
| XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation
November 27, 2009 at 9:21 am
|
| DELRAY BEACH, Fla.--(BUSINESS WIRE)--XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that is has become a national sponsor of the Arthritis Foundation at the National Proud Sponsor level. “As one of the largest and most well-respected nonprofit organizations dedicated to arthritis research and public health education, the Arthritis Foundation is on an important mission to improve the
 | Media Files
ViewMedia?mgid=195645&vid=2 (2 KB)
|
| ChemGenex's Marketing Authorization Application for Omacetaxine Mepesuccinate Validated by the European Medicines Agency
November 27, 2009 at 8:00 am
|
| MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that the European Medicines Agency ("EMEA") has determined that the Marketing Authorization Application ("MAA") for omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation is valid. Validation of the MAA indicates that ChemGenex’s application, submitted
 |
| Research and Markets: This Report Offers the Basis for Organizations to Develop Their Own Blueprint for Managing the Opportunities and Threats to the Pharmaceutical Supply Chain
November 27, 2009 at 7:45 am
|
| DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/1dfb96/supply_chain_in_th) has announced the addition of the "Supply Chain in the Pharmaceutical Industry" report to their offering. The pharmaceutical and healthcare industry is hugely complex because it involves so many markets, products, processes and intermediaries. It is also heavily regulated, global, and used by everyone at some stage in their life. No wonder the supply chain for delivery of healthca
 |
| Celgene Corporation to Present at the NASDAQ OMX 23rd Investor Program
November 27, 2009 at 7:30 am
|
| SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced its presentation at the NASDAQ OMX 23rd Investor Program on Tuesday, December 1, 2009 at 8:30 a.m. GMT will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily
 | Media Files
ViewMedia?mgid=127432&vid=2 (2 KB)
|
| Research and Markets: Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks
November 27, 2009 at 7:00 am
|
| DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8cd274/key_players_and_in) has announced the addition of the "Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks" report to their offering. Nutraceuticals are bioactive compounds with properties beneficial to health that are often concentrated extracts from fruits, herbs, seeds, specific lipids and vegetables. Nutraceuticals are often used to
 |
| Research and Markets: Prostate Cancer Therapeutics - a Global Market Perspective
November 27, 2009 at 7:00 am
|
| DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/50344c/prostate_cancer_th) has announced the addition of the "Prostate Cancer Therapeutics - A Global Market Perspective" report to their offering. Growth in prostate cancer therapies can be attributed to the increase in number of prostate cancer incidences in men aged more than 60 years. Given the longevity of an average individual, and the rapidly aging world population, the risk of prostate cancer stands
 |
| Research and Markets: Pain Management - Global Trends: Availability of Generic Drugs, Emergence of Pain Management Clinics, and the Advent of New Drugs
November 27, 2009 at 6:10 am
|
| DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/90de9b/pain_management) has announced the addition of the "Pain Management - Global Trends" report to their offering. Widespread availability of generic drugs, emergence of pain management clinics, and the advent of new drugs have accelerated the pace of growth in the pain management market. Healthcare reforms and reimbursement structure continue to shape demand for services, drugs and devices. The market i
 |
| Tripep Carries out a Rights Issue
November 27, 2009 at 6:02 am
|
| STOCKHOLM--(BUSINESS WIRE)--The Board of Directors of Tripep AB (publ)(STO:TPEP) has on the 27th of November 2009, based on the authorization by the Annual General Meeting resolved to carry out a rights issue. Every existing share entitles to subscribe for one new share during the period 7 – 21 December 2009 at the subscription price SEK 0.50. If the rights issue is subscribed in full it will give the company a capital injection of SEK 17.8 m (before transaction costs which is estimated to
 |
| Research and Markets: Parkinson Disease Therapy Area Pipeline Report
November 27, 2009 at 5:03 am
|
| DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/4bfafd/parkinson_disease) has announced the addition of the "Parkinson Disease Therapy Area Pipeline Report" report to their offering. Life Science Analytics, Parkinson Disease Therapy Area Pipeline Report contains detailed information on the parkinson disease drug pipeline. This report provides insight into the pipeline status of parkinson disease drugs by company and by stage as well as a summary of the l
 | 
|
没有评论:
发表评论